GCM
GBIO

Graham Capital Management’s Generation Bio GBIO Stock Holding History

Graham Capital Management’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,142
Closed -$80K – 932
2021
Q4 		$80K Buy
+1,142
New +$199K ﹤0.01% 514

Other funds holding GBIO

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return

Graham Capital Management's GBIO Position: Q1 2022 in Review

Graham Capital Management sold out of Generation Bio (GBIO) in Q1 2022, closing a stake of 1,142 shares — an estimated $80K sold.

Graham Capital Management first reported a position in GBIO in Q4 2021 and held it in 1 quarter. The position peaked at $80K in Q4 2021. 88 funds tracked by Wall St. Rank hold GBIO as of Q1 2022.

  • Graham Capital Management reported no remaining Generation Bio position as of Q1 2022 after selling out during the quarter.
  • Graham Capital Management sold 1,142 Generation Bio shares in Q1 2022, an estimated $80K.
  • Graham Capital Management first reported a position in Generation Bio in Q4 2021 and held it in 1 quarter.
  • Graham Capital Management's Generation Bio position peaked at $80K in Q4 2021.
  • 88 funds tracked by Wall St. Rank held Generation Bio as of Q1 2022.

Based on Graham Capital Management's 13F filing for Q1 2022, filed 16 May 2022.